Menu

Category: Judicial

Bristol Myers Squibb/Celgene Myeloma Drugs: Patient-Safety or Profit Motive? Part 5

In Federal, Judicial, Legislative, Pharma Industry, Regulatory, Research/Reports163 Views Tom Mirga
Our six-part investigative series takes an in-depth look into a question often asked by 340B providers: Why can’t they access 340B pricing on one of Bristol Myers Squibb/Celgene’s most profitable drug products? We also delve into serious fraud allegations, Congressional oversight, and the possibility of a renewed focus on this contentious area under new leadership at the U.S. Health and Human Services Department. Throughout the series, we also provide BMS/Celgene's viewpoint, their justification for their drug pricing practices, limited distribution policies and why they believe they are following the law.
Last September, the Democratic-controlled U.S. House Oversight and Reform Committee released a 45-page report focused on Celgene and Bristol Myers Squibb’s (BMS’s) nearly two dozen price increases on Revlimid from 2005, when Celgene bought the drug, through 2019. It was …
Read More »

Bristol Myers Squibb/Celgene Myeloma Drugs: Patient-Safety or Profit Motive? Part 4

In Federal, Judicial, Legislative, Pharma Industry, Regulatory, Research/Reports375 Views Tom Mirga
Our six-part investigative series takes an in-depth look into a question often asked by 340B providers: Why can’t they access 340B pricing on one of Bristol Myers Squibb/Celgene’s most profitable drug products? We also delve into serious fraud allegations, Congressional oversight, and the possibility of a renewed focus on this contentious area under new leadership at the U.S. Health and Human Services Department. Throughout the series, we also provide BMS/Celgene's viewpoint, their justification for their drug pricing practices, limited distribution policies and why they believe they are following the law.
The impact on health care providers of being unable to access Revlimid at the 340B price is significant, financially and in terms of patient care, according to numerous health system representatives that 340B Report interviewed. (All current and former health …
Read More »

Bristol Myers Squibb/Celgene Myeloma Drugs: Patient-Safety or Profit Motive? Part 3

In Federal, Judicial, Legislative, Pharma Industry, Regulatory, Research/Reports497 Views Tom Mirga
Our six-part investigative series takes an in-depth look into a question often asked by 340B providers: Why can’t they access 340B pricing on one of Bristol Myers Squibb/Celgene’s most profitable drug products? We also delve into serious fraud allegations, Congressional oversight, and the possibility of a renewed focus on this contentious area under new leadership at the U.S. Health and Human Services Department. Throughout the series, we also provide BMS/Celgene's viewpoint, their justification for their drug pricing practices, limited distribution policies and why they believe they are following the law.
The myeloma drugs Revlimid and Pomalyst are analogues of Thalomid, aka thalidomide—a drug that still haunts those who remember the late 1950s and early 1960s. Marketed mainly in Europe as an over the counter sedative and morning sickness medicine for …
Read More »

Bristol Myers Squibb/Celgene Myeloma Drugs: Patient-Safety or Profit Motive? Part 2

In Federal, Judicial, Legislative, Pharma Industry, Regulatory, Research/Reports681 Views Tom Mirga
Our six-part investigative series takes an in-depth look into a question often asked by 340B providers: Why can’t they access 340B pricing on one of Bristol Myers Squibb/Celgene’s most profitable drug products? We also delve into serious fraud allegations, Congressional oversight, and the possibility of a renewed focus on this contentious area under new leadership at the U.S. Health and Human Services Department. Throughout the series, we also provide BMS/Celgene's viewpoint, their justification for their drug pricing practices, limited distribution policies and why they believe they are following the law.
Editor’s note: We invited Bristol Myers Squibb (BMS), which bought Celgene in November 2019, to respond to allegations of illegal or questionable conduct by Celgene with respect to its myeloma drugs and the 340B program. BMS said: “Bristol Myers Squibb …
Read More »

Bristol Myers Squibb/Celgene Myeloma Drugs: Patient-Safety or Profit Motive? Part 1

In Federal, Judicial, Legislative, Pharma Industry, Regulatory, Research/Reports958 Views Tom Mirga
Our six-part investigative series takes an in-depth look into a question often asked by 340B providers: Why can’t they access 340B pricing on one of Bristol Myers Squibb/Celgene’s most profitable drug products? We also delve into serious fraud allegations, Congressional oversight, and the possibility of a renewed focus on this contentious area under new leadership at the U.S. Health and Human Services Department. Throughout the series, we also provide BMS/Celgene's viewpoint, their justification for their drug pricing practices, limited distribution policies and why they believe they are following the law.

Part 1 of 6—Why Can So Few 340B Hospitals Buy and Dispense the Highly Profitable Cancer Drug Revlimid?

Possibly more than a thousand hospitals in the 340B drug discount program can’t buy or dispense Revlimid, a widely-used oral drug to

…
Read More »

Novartis Says Its Reputation Has Been Injured By HRSA’s 340B Demand Letter

In Federal, Judicial650 Views Tom Mirga
Novartis said HRSA's demand letter is hindering its “ability to recruit talent and build relationships with the stakeholders necessary to develop pharmaceuticals that patients need.” | Shutterstock
Drug manufacturer Novartis told a judge last week that the government’s May 17 public statement that the company’s actions have resulted in overcharges and are in direct violation of the 340B statute has injured Novartis’ reputation among its customers and …
Read More »

Judge Declines to Issue Stays Against HRSA Stemming from its May 17 Demand Letters

In Federal, Judicial542 Views Tom Mirga
A federal district judge in Trenton, N.J., this week denied drug makers’ Novo Nordisk and Sanofi’s motions to temporarily stop federal health officials from forcing the companies to immediately resume offering 340B pricing when covered entities use contract pharmacies.
A federal district judge in Trenton, N.J., this week denied drug makers’ Novo Nordisk and Sanofi’s motions to temporarily stop federal health officials from forcing the companies to immediately resume offering 340B pricing when covered entities use contract pharmacies. If …
Read More »

340B Hospitals Ask Supreme Court Again to End Steep Medicare Drug Payment Cut

In Federal, Judicial134 Views Tom Mirga
Hospital groups have urged the U.S. Supreme Court again to set aside a deep cut in Medicare Part B drug reimbursement for 340B purchased drugs. | Shutterstock
National hospital groups urged the U.S. Supreme Court last Friday to review and reverse a federal appellate decision upholding a steep cut in hospitals’ Medicare Part B reimbursement for 340B-purchased drugs.

Please Login or Become a

…
Read More »

BREAKING: Novartis Sues HRSA in Defense of its 340B Contract Pharmacy Policy

In Breaking, Federal, Judicial993 Views Tom Mirga
Novartis sued HRSA yesterday to stop it from enforcing its interpretation of the 340B statute's contract pharmacy requirements, and from imposing civil monetary penalties against Novartis for alleged violations. | Shutterstock
Novartis Pharmaceuticals has sued the U.S. Health Resources and Services Administration (HRSA) over the agency’s May 17 letter telling the company its restrictions on 340B pricing to covered entities that use contract pharmacies are illegal.

Please

…
Read More »

Late Breaking Developments in Lilly and AstraZeneca’s 340B Contract Pharmacy Lawsuits

In Breaking, Federal, Judicial2111 Views Tom Mirga
A federal district judge in Indianapolis late this afternoon declined to temporarily restrain federal health officials from requiring drug maker Eli Lilly, based on a May 17 enforcement letter, to provide 340B discounts on drugs dispensed by contract pharmacies. | Shutterstock
A federal district judge in Indianapolis late this afternoon declined to temporarily restrain federal health officials from requiring drug maker Eli Lilly, based on a May 17 enforcement letter, to provide 340B discounts on drugs dispensed by contract pharmacies. …
Read More »